Aquestive Therapeutics, Inc. Paid-in-Kind Interest
Aquestive Therapeutics, Inc. (AQST) reported Paid-in-Kind Interest of $0 for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-05.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:PaidInKindInterest · last filed 2020-05-05
- Aquestive Therapeutics, Inc. paid-in-kind interest for the quarter ending 2020-03-31 was $0.00, a 100.00% decline year-over-year.
- Aquestive Therapeutics, Inc. paid-in-kind interest for the quarter ending 2019-12-31 was $335.00K, a 41.35% increase year-over-year.
- Aquestive Therapeutics, Inc. paid-in-kind interest for the quarter ending 2019-09-30 was -$481.00K, a 3106.25% decline year-over-year.
- Aquestive Therapeutics, Inc. paid-in-kind interest for the quarter ending 2019-06-30 was -$22.00K.
- Aquestive Therapeutics, Inc. paid-in-kind interest for fiscal 2019 was $359.00K, a 51.48% increase from fiscal 2018.
- Aquestive Therapeutics, Inc. paid-in-kind interest for fiscal 2018 was $237.00K, a 618.18% increase from fiscal 2017.
- Aquestive Therapeutics, Inc. paid-in-kind interest for fiscal 2017 was $33.00K.
| Period end | Paid-in-Kind Interest 3 month | Paid-in-Kind Interest 6 month | Paid-in-Kind Interest 9 month | Paid-in-Kind Interest 12 month | Paid-in-Kind Interest 12 month as first filed |
|---|---|---|---|---|---|
| 2020-03-31 | $0.00 10-Q · filed 2020-05-05 | $335.00K derived: sum of 2 quarters · filed 2020-05-05 | -$146.00K derived: sum of 3 quarters · filed 2020-05-05 | -$168.00K derived: sum of 4 quarters · filed 2020-05-05 | |
| 2019-12-31 | $335.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | -$146.00K derived: sum of 2 quarters · filed 2020-03-11 | -$168.00K derived: sum of 3 quarters · filed 2020-03-11 | $359.00K 10-K · filed 2020-03-11 | |
| 2019-09-30 | -$481.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | -$503.00K derived: sum of 2 quarters · filed 2019-11-05 | $24.00K 10-Q · filed 2019-11-05 | $261.00K derived: sum of 4 quarters · filed 2020-05-05 | |
| 2019-06-30 | -$22.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $505.00K 10-Q · filed 2019-08-06 | $742.00K derived: sum of 3 quarters · filed 2020-05-05 | $758.00K derived: sum of 4 quarters · filed 2020-05-05 | |
| 2019-03-31 | $527.00K 10-Q · filed 2020-05-05 | $764.00K derived: sum of 2 quarters · filed 2020-05-05 | $780.00K derived: sum of 3 quarters · filed 2020-05-05 | ||
| 2018-12-31 | $237.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $253.00K derived: sum of 2 quarters · filed 2020-03-11 | $237.00K 10-K · filed 2020-03-11 | $0.00 10-K · filed 2019-03-14 | |
| 2018-09-30 | $16.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $0.00 10-Q · filed 2019-11-05 | |||
| 2018-06-30 | -$16.00K 10-Q · filed 2018-09-04 | ||||
| 2017-12-31 | $17.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $33.00K derived: sum of 2 quarters · filed 2019-03-14 | $33.00K 10-K · filed 2019-03-14 | ||
| 2017-09-30 | $16.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $16.00K 10-Q · filed 2018-11-06 | |||
| 2017-06-30 | $0.00 10-Q · filed 2018-09-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |